Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P M Ridker

Showing results (1-10 of 203) with videos related to

Pageof 21
Sort By:
Lancet (London, England)|October 5, 2001
Role of inflammatory biomarkers in prediction of coronary heart diseaseP M Ridker
Trends in Cardiovascular Medicine|January 15, 2011
An epidemiologic reassessment of lipoprotein(a) and atherothrombotic riskP M Ridker
Journal of Thrombosis and Haemostasis : JTH|June 29, 2004
Long-term low-dose warfarin use is effective in the prevention of recurrent venous thromboembolism: yesP M Ridker
European Heart Journal|September 18, 1998
Intercellular adhesion molecule (ICAM-1) and the risks of developing atherosclerotic diseaseP M Ridker
Vascular Medicine (London, England)|July 17, 1998
Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trialP M Ridker
European Heart Journal|March 27, 2002
Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trialP M Ridker
Circulation|May 20, 1998
Inflammation, infection, and cardiovascular risk: how good is the clinical evidence?P M Ridker
Thrombosis and Haemostasis|November 1, 1996
Factor V Leiden and recurrent venous thromboembolismP M Ridker
Current Cardiology Reports|September 12, 2000
Duration and intensity of anticoagulation among patients with genetic predispositions to venous thrombosisP M Ridker
Circulation|April 3, 2001
High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular diseaseP M Ridker
Pageof 21

Showing results (1-10 of 203) with videos related to

Sort By:
Pageof 21
Lancet (London, England)|October 5, 2001
Role of inflammatory biomarkers in prediction of coronary heart diseaseP M Ridker
Trends in Cardiovascular Medicine|January 15, 2011
An epidemiologic reassessment of lipoprotein(a) and atherothrombotic riskP M Ridker
Journal of Thrombosis and Haemostasis : JTH|June 29, 2004
Long-term low-dose warfarin use is effective in the prevention of recurrent venous thromboembolism: yesP M Ridker
European Heart Journal|September 18, 1998
Intercellular adhesion molecule (ICAM-1) and the risks of developing atherosclerotic diseaseP M Ridker
Vascular Medicine (London, England)|July 17, 1998
Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the Prevention of Recurrent Venous Thromboembolism (PREVENT) trialP M Ridker
European Heart Journal|March 27, 2002
Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trialP M Ridker
Circulation|May 20, 1998
Inflammation, infection, and cardiovascular risk: how good is the clinical evidence?P M Ridker
Thrombosis and Haemostasis|November 1, 1996
Factor V Leiden and recurrent venous thromboembolismP M Ridker
Current Cardiology Reports|September 12, 2000
Duration and intensity of anticoagulation among patients with genetic predispositions to venous thrombosisP M Ridker
Circulation|April 3, 2001
High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular diseaseP M Ridker
Pageof 21